Search

Your search keyword '"Leyen, Heiko"' showing total 201 results
Start Over Author "Leyen, Heiko"
201 results on '"Leyen, Heiko"'

1. Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial

Author

Bavendiek, Udo, Großhennig, Anika, Schwab, Johannes, Berliner, Dominik, Liu, Xiaofei, Maier, Lars, Gaspar, Thomas, Rieth, Andreas, Philipp, Sebastian, Hambrecht, Rainer, Westenfeld, Ralf, Münzel, Thomas, Winkler, Sebastian, Hülsmann, Martin, Westermann, Dirk, Zdravkovic, Marja, Lichtinghagen, Ralf, von der Leyen, Heiko, Zimmermann, Silke, Veltmann, Christian, Böhm, Michael, Störk, Stefan, Koch, Armin, and Bauersachs, Johann

Published
2023
Full Text
View/download PDF

2. Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – A post-hoc analysis of the PRIORITY randomized clinical trial

Author

Rotbain Curovic, Viktor, Tofte, Nete, Lindhardt, Morten, Adamova, Katarina, Bakker, Stephan J.L., Beige, Joachim, Beulens, Joline W.J., Birkenfeld, Andreas L., Currie, Gemma, Delles, Christian, Dimos, Ingo, Francová, Lidmila, Frimodt-Møller, Marie, Girman, Peter, Göke, Rüdiger, Hansen, Tine W., Havrdova, Tereza, Kooy, Adriaan, Laverman, Gozewijnw D., Mischak, Harald, Navis, Gerjan, Nijpels, Giel, Noutsou, Marina, Ortiz, Alberto, Parvanova, Aneliya, Persson, Frederik, Petrie, John R., Ruggenenti, Piero L., Rutters, Femke, Rychlík, Ivan, Siwy, Justyna, Spasovski, Goce, Speeckaert, Marijn, Trillini, Matias, Zürbig, Petra, von der Leyen, Heiko, and Rossing, Peter

Published
2023
Full Text
View/download PDF

3. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study

Author

Staessen, Jan A, Wendt, Ralph, Yu, Yu-Ling, Kalbitz, Sven, Thijs, Lutgarde, Siwy, Justyna, Raad, Julia, Metzger, Jochen, Neuhaus, Barbara, Papkalla, Armin, von der Leyen, Heiko, Mebazaa, Alexandre, Dudoignon, Emmanuel, Spasovski, Goce, Milenkova, Mimoza, Canevska-Taneska, Aleksandra, Lazo, Mercedes Salgueira, Psichogiou, Mina, Rajzer, Marek W, Fulawka, Lukasz, Dzitkowska-Zabielska, Magdalena, Weiss, Guenter, Feldt, Torsten, Stegemann, Miriam, Normark, Johan, Zoufaly, Alexander, Schmiedel, Stefan, Seilmaier, Michael, Rumpf, Benedikt, Banasik, Mirosław, Krajewska, Magdalena, Catanese, Lorenzo, Rupprecht, Harald, Czerwienska, Beata, Peters, Björn, Nilsson, Åsa, Rothfuss, Katja, Lübbert, Christoph, Mischak, Harald, Beige, Joachim, Ermisch, Jörg, Kellner, Nils, Peruth-Stutzmann, Lydia, Schroth, Stefanie, Schmidt, Jonathan, Schmidt, Ulrike, Breuer, Daniel, Abeud, Fariza, Fournier, Marie-Celine, Louadah, Badr, Molas, Rocio, Rojas, Fraile Loreto, García, Fabiola Alonso, Sánchez, Isabel Garcia, Hrom, Ioana Cezara, Więczek., Andrzej, Schwab, Matthias, K Asayama, Kei, Hansen, Tine W, Maestre, Gladys E, Basoulis, Dimitrios, Karamanakos., Georgios, Lis, Pawel, Olszanecka, Agnieszka, Bellmann-Weiler, Rosa, Lanser, Lucas, Edin, Alicia, Forsell, Matthias NE, Stegmayr, Bernd, Jensen, Björn-Erik Ole, Orth, Hans-Martin, Borstel, Sylke, Mikolajewska, Agata, Hecking, Manfred, Schmölz, Lukas, Hoffmann, Michał, Narkiewicz, Krzysztof, Matera-Witkiewicz, Agnieszka, Zachciał, Justyna, Litwin, Monika, Marciniak, Patrycja, Salgueira Lazo, Mercedes, Fuławka, Łukasz, Rupprecht, Harald D, and Czerwieńska, Beata

Published
2022
Full Text
View/download PDF

4. A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients

Author

Wendt, Ralph, Thijs, Lutgarde, Kalbitz, Sven, Mischak, Harald, Siwy, Justyna, Raad, Julia, Metzger, Jochen, Neuhaus, Barbara, Leyen, Heiko von der, Dudoignon, Emmanuel, Mebazaa, Alexandre, Spasovski, Goce, Milenkova, Mimoza, Canevska-Talevska, Aleksandra, Czerwieńska, Beata, Wiecek, Andrzej, Peters, Björn, Nilsson, Åsa, Schwab, Matthias, Rothfuss, Katja, Lübbert, Christoph, Staessen, Jan A., and Beige, Joachim

Published
2021
Full Text
View/download PDF

5. Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study.

Author

Wasehuus, Victor, Rotbain Curovic, Viktor, Tofte, Nete, Lindhardt, Morten, Currie, Gemma, Delles, Christian, Frimodt‐Møller, Marie, Mischak, Harald, von der Leyen, Heiko, Hansen, Tine Willum, Kümler, Thomas, Persson, Frederik, Rossing, Peter, Stefansen, Rikke, Campbell, Maria Athena, Zimmermann, Silke, Rädisch, Brit, Hävemeier, Anika, Busmann, Annette, and Wittkop, Ulrike

Abstract

Aims: This study aimed to explore the effect of discontinuation of long‐term spironolactone treatment on markers of kidney function in individuals with type 2 diabetes (T2D) at high risk of kidney disease enrolled in the Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria (PRIORITY) study. Materials and Methods: An observational study following the nested randomised part of the PRIORITY study was conducted. A total of 115 individuals with T2D and normoalbuminuria but high risk for progression based on urinary proteomics, randomised to daily spironolactone (n = 50) or placebo (n = 65) for a median of 2.5 years, were re‐examined approximately 6 weeks after the final visit in the PRIORITY study. Primary endpoint was relative change in geometric mean of urinary albumin‐creatinine ratio (UACR) between the final visit in PRIORITY (baseline) and follow‐up. Secondary endpoints were change in estimated glomerular filtration rate (eGFR), systolic blood pressure (SBP) and serum potassium. Results: No change in UACR was observed in neither the spironolactone (geometric mean change: 17%; 95% CI −12, 55; p = 0.28) nor the placebo (5%; 95% CI −13, 26; p = 0.63) group at follow‐up. No difference in UACR between the groups was observed at follow‐up (relative difference in geometric mean: 11%, 95% CI −26, 67; p = 0.60). For eGFR and SBP, an increase after discontinuation of spironolactone was observed, as well as for SBP after placebo discontinuation. Potassium levels were lower after discontinuation of spironolactone, but higher after placebo discontinuation (all p < 0.05). Conclusions: UACR did not change after discontinuation of long‐term treatment with spironolactone. However, an increase in eGFR was observed supporting a haemodynamic effect of spironolactone in the kidneys. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

7. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Author

Weissinger, Eva M., Metzger, Jochen, Schleuning, Michael, Schmid, Christoph, Messinger, Diethelm, Beutel, Gernot, Wagner-Drouet, Eva-Maria, Schetelig, Johannes, Baurmann, Herrad, Rank, Andreas, Stolzl, Friedrich, Schäfer-Eckart, Kerstin, Westphal, Karin, Bethge, Wolfgang, von Harsdorf, S., Bunjes, Donald W., Heidenreich, Daniela, Klein, Stefan, Holler, Ernst, Kreipe, Hans H., Jonigk, Danny, Türüchanow, Irina, Raad, Julia, Papkalla, Armin, von der Leyen, Heiko, Hambach, Lothar, Hamwi, Iyas, Ehrlich, Steve, Krauter, Jurgen, Stadler, Michael, and Ganser, Arnold

Published
2021
Full Text
View/download PDF

8. Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer

Author

Scholl, Suzy M, Beal, Jonas, de Koning, Leanne, Girard, Elodie, Popovic, Marina, de la Rochefordière, Anne, Lecuru, Fabrice, Fourchotte, Virginie, Ngo, Charlotte, Floquet, Anne, Berns, Els MJJ, Kenter, Gemma, Gestraud, Pierre, von der Leyen, Heiko, Lecerf, Charlotte, Puard, Vincent, Roman, Sergio Roman, Latouche, Aurelien, Kereszt, Attila, Balint, Balazs, Rouzier, Roman, and Kamal, Maud

Published
2020
Full Text
View/download PDF

9. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Author

Zimmermann, Silke, Rädisch, Brit, Hävemeier, Anika, Busmann, Annette, Wittkop, Ulrike, Neuhaus, Barbara, Ax-Smolarski, Regina, Zieglschmid, Veit, Bollweber, Eva, Wölk, Heidrun, Curovic, Viktor R., Tougaard, Ninna H., Eickhoff, Mie K., Pilemann-Lyberg, Sascha, Winther, Signe A., Rosenlund, Signe V., Hansen, Tine W., von Scholten, Bernt J., Hansen, Christian S., Zobel, Emilie H., Laursen, Jens C., Theilade, Simone, Jelstrup, Lone, Juhl, Tina R., Riis, Dorthe, Hermann, Jessie A., Lundgaard, Anne G., Halkjær, Maja L.D., Aabo, Lene, Frost Lerche, Therese, Lajer, Maria, Stefansen, Rikke J., Campbell, Maria A., Durban, Annika, Raad, Julia, Prigge, Michael, Schiemann, Marco, Wilson, Robbie, Kean, Sharon, Douglas, Elizabeth, Surtees, Pamela, Gant, Christina, Yeung, Stanley M.H., Hagedoorn, Ilse, Flynn, Joanne, Galloway, Joe, Brooksbank, Katriona, Aparicio, Carolina, Iliev, Ilian P., Nones, Francesco, Lo Bue, Francesca, Melacini, Daniela, Cugini, Daniela, Prandini, Silvia, Lecchi, Verusca, Yakymchuk, Svitlana, Gherardi, Giulia, Villa, Alessandro, Villa, Davide, Gaspari, Flavio, Cannata, Antonio N., Ferrari, Silvia, Stucchi, Nadia, Albrechtová, Šárka, Eldeik, Elina, Amanaki, Renata, Fernandez-Fernandez, Beatriz, Sanchez-Rodriguez, Jinny, Vázquez, Clotilde, Sanz, Ana B., Sanchez-Niño, Maria D., Ramos, Adrian M., Gonzalo, Maria Á., Schmidt, Ulrike, Selim, Gjulsen, Gjorgovski, Tatjana, Stratrova, Slavica S., Stojceva-Taneva, Olivera, Schutten-Westerneng, Petra, Wierbos, Brenda, Huvers, Frank, De Bruin, Anneke K., Lapauw, Bruno, de Man, Elsie, Rokegem, Kelly, Inion, Sabien, Kreutzmann, Kristin, Dewettinck, Isabelle, Boukens-de Graaf, Caroline, Clerc-de Jong, Ferrina, Entius, Jannet, Nannings, Marian, van Steenderen, Suzy, Petry, Friedrich W., Kilic, Ceyda, Tofte, Nete, Lindhardt, Morten, Adamova, Katarina, Bakker, Stephan J L, Beige, Joachim, Beulens, Joline W J, Birkenfeld, Andreas L, Currie, Gemma, Delles, Christian, Dimos, Ingo, Francová, Lidmila, Frimodt-Møller, Marie, Girman, Peter, Göke, Rüdiger, Havrdova, Tereza, Heerspink, Hiddo J L, Kooy, Adriaan, Laverman, Gozewijn D, Mischak, Harald, Navis, Gerjan, Nijpels, Giel, Noutsou, Marina, Ortiz, Alberto, Parvanova, Aneliya, Persson, Frederik, Petrie, John R, Ruggenenti, Piero L, Rutters, Femke, Rychlík, Ivan, Siwy, Justyna, Spasovski, Goce, Speeckaert, Marijn, Trillini, Matias, Zürbig, Petra, von der Leyen, Heiko, and Rossing, Peter

Published
2020
Full Text
View/download PDF

10. Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial

Author

Sauer, Martin G., Lang, Peter J., Albert, Michael H., Bader, Peter, Creutzig, Ursula, Eyrich, Matthias, Greil, Johann, Gruhn, Bernd, Holter, Wolfgang, Klingebiel, Thomas, Kremens, Bernhard, von der Leyen, Heiko, Mauz-Körholz, Christine, Meisel, Roland, Mischke, Kirsten, Müller, Ingo, Niemeyer, Charlotte M., Peters, Christina, Pohler, Christine, Reinhardt, Dirk, Burkhardt, Birgit, Schlegel, Paul G., Schulz, Ansgar S., Schrum, Johanna, Sedlacek, Petr, Strahm, Brigitte, Woessmann, Wilhelm, Handgretinger, Rupert, Zimmermann, Martin, and Borkhardt, Arndt

Published
2020
Full Text
View/download PDF

11. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome

Author

Scholl, Suzy, Popovic, Marina, de la Rochefordiere, Anne, Girard, Elodie, Dureau, Sylvain, Mandic, Aljosa, Koprivsek, Katarina, Samet, Nina, Craina, Marius, Margan, Madalin, Samuels, Sanne, Zijlmans, Henry, Kenter, Gemma, Hillemanns, Peter, Dema, Sorin, Dema, Alis, Malenkovic, Goran, Djuran, Branislav, Floquet, Anne, Garbay, Delphine, Guyon, Frédéric, Colombo, Pierre Emmanuel, Fabbro, Michel, Kerr, Christine, Ngo, Charlotte, Lecuru, Fabrice, Campo, Eleonor Rivin del, Coutant, Charles, Marchal, Frédéric, Mesgouez-Nebout, Nathalie, Fourchotte, Virginie, Feron, Jean Guillaume, Morice, Philippe, Deutsch, Eric, Wimberger, Pauline, Classe, Jean-Marc, Gleeson, Noreen, von der Leyen, Heiko, Minsat, Mathieu, Dubot, Coraline, Gestraud, Pierre, Kereszt, Attila, Nagy, Istvan, Balint, Balazs, Berns, Els, Jordanova, Ekaterina, Saint-Jorre, Nicolas de, Savignoni, Alexia, Servant, Nicolas, Hupe, Philippe, de Koning, Leanne, Fumoleau, Pierre, Rouzier, Roman, and Kamal, Maud

Published
2019
Full Text
View/download PDF

12. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

Author

Wedemeyer, Heiner, Yurdaydin, Cihan, Hardtke, Svenja, Caruntu, Florin Alexandru, Curescu, Manuela G, Yalcin, Kendal, Akarca, Ulus S, Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V, Keskin, Onur, Port, Kerstin, Radu, Monica, Celen, Mustafa K, Idilman, Ramazan, Weber, Kristina, Stift, Judith, Wittkop, Ulrike, Heidrich, Benjamin, Mederacke, Ingmar, von der Leyen, Heiko, Dienes, Hans Peter, Cornberg, Markus, Koch, Armin, and Manns, Michael P

Published
2019
Full Text
View/download PDF

13. Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Author

Anastasiou, Olympia E., primary, Caruntu, Florin A., additional, Curescu, Manuela G., additional, Yalcin, Kendal, additional, Akarca, Ulus S., additional, Gürel, Selim, additional, Zeuzem, Stefan, additional, Erhardt, Andreas, additional, Lüth, Stefan, additional, Papatheodoridis, George V., additional, Keskin, Onur, additional, Port, Kerstin, additional, Radu, Monica, additional, Celen, Mustafa K., additional, Idilman, Ramazan, additional, Heidrich, Benjamin, additional, Mederacke, Ingmar, additional, von der Leyen, Heiko, additional, Kahlhöfer, Julia, additional, von Karpowitz, Maria, additional, Hardtke, Svenja, additional, Cornberg, Markus, additional, Yurdaydin, Cihan, additional, and Wedemeyer, Heiner, additional

Published
2023
Full Text
View/download PDF

15. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study

Author

Deterding, Katja, Spinner, Christoph D, Schott, Eckart, Welzel, Tania M, Gerken, Guido, Klinker, Hartwig, Spengler, Ulrich, Wiegand, Johannes, zur Wiesch, Julian Schulze, Pathil, Anita, Cornberg, Markus, Umgelter, Andreas, Zöllner, Caroline, Zeuzem, Stefan, Papkalla, Armin, Weber, Kristina, Hardtke, Svenja, von der Leyen, Heiko, Koch, Armin, von Witzendorff, Dorothee, Manns, Michael P, and Wedemeyer, Heiner

Published
2017
Full Text
View/download PDF

17. Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.

Author

Anastasiou, Olympia E., Caruntu, Florin A., Curescu, Manuela G., Yalcin, Kendal, Akarca, Ulus S., Gürel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George V., Keskin, Onur, Port, Kerstin, Radu, Monica, Celen, Mustafa K., Idilman, Ramazan, Heidrich, Benjamin, Mederacke, Ingmar, von der Leyen, Heiko, Kahlhöfer, Julia, and von Karpowitz, Maria

Subjects
HEPATITIS D, HEPATITIS D virus, TENOFOVIR, CIRRHOSIS of the liver, HEPATOCELLULAR carcinoma
Abstract

Background & Aims: Until recently, pegylated interferon‐alfa‐2a (PEG‐IFNa) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). Treatment with PEG‐IFNa with or without tenofovir disoproxil fumarate (TDF) for 96 weeks resulted in HDV RNA suppression in 44% of patients at the end of therapy but did not prevent short‐term relapses within 24 weeks. The virological and clinical long‐term effects after prolonged PEG‐IFNa‐based treatment of hepatitis D are unknown. Methods: In the HIDIT‐II study patients (including 40% with liver cirrhosis) received 180 μg PEG‐IFNa weekly plus 300 mg TDF once daily (n = 59) or 180 μg PEG‐IFNa weekly plus placebo (n = 61) for 96 weeks. Patients were followed until week 356 (5 years after end of therapy). Results: Until the end of follow‐up, 16 (13%) patients developed liver‐related complications (PEG‐IFNa + TDF, n = 5 vs PEG‐IFNa + placebo, n = 11; p =.179). Achieving HDV suppression at week 96 was associated with decreased long‐term risk for the development of hepatocellular carcinoma (p =.04) and hepatic decompensation (p =.009). Including complications irrespective of PEG‐IFNa retreatment status, the number of patients developing serious complications was similar with (3/18) and without retreatment with PEG‐IFNa (16/102, p >.999) but was associated with a higher chance of HDV‐RNA suppression (p =.024, odds ratio 3.9 [1.3–12]). Conclusions: Liver‐related clinical events were infrequent and occurred less frequently in patients with virological responses to PEG‐IFNa treatment. PEG‐IFNa treatment should be recommended to HDV‐infected patients until alternative therapies become available. Retreatment with PEG‐IFNa should be considered for patients with inadequate response to the first course of treatment. Clinical Trial registration: NCT00932971. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Author

Anastasiou, Olympia Aevdoxia, primary, Caruntu, Florin Alexandru, additional, Curescu, Manuela Gabriela, additional, Yalcin, Kendal, additional, Akarca, Ulus S, additional, Gurel, Selim, additional, Zeuzem, Stefan, additional, Erhardt, Andreas, additional, Lüth, Stefan, additional, Papatheodoridis, George, additional, Keskin, Onur, additional, Port, Kerstin, additional, Radu, Monica, additional, Celen, Mustafa, additional, Idilman, Ramazan, additional, Heidrich, Benjamin, additional, Mederacke, Ingmar, additional, von der Leyen, Heiko, additional, Kahlhöfer, Julia, additional, von Karpowitz, Maria, additional, Hardtke, Svenja, additional, Cornberg, Markus, additional, Yurdaydin, Cihan, additional, and Wedemeyer, Heiner, additional

Published
2023
Full Text
View/download PDF

19. Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial

Author

Sauer, Martin G., Lang, Peter J., Albert, Michael H., Bader, Peter, Creutzig, Ursula, Eyrich, Matthias, Greil, Johann, Gruhn, Bernd, Holter, Wolfgang, Klingebiel, Thomas, Kremens, Bernhard, von der Leyen, Heiko, Mauz-Körholz, Christine, Meisel, Roland, Mischke, Kirsten, Müller, Ingo, Niemeyer, Charlotte M., Peters, Christina, Pohler, Christine, Reinhardt, Dirk, Burkhardt, Birgit, Schlegel, Paul G., Schulz, Ansgar S., Schrum, Johanna, Sedlacek, Petr, Strahm, Brigitte, Woessmann, Wilhelm, Handgretinger, Rupert, Zimmermann, Martin, and Borkhardt, Arndt

Published
2020
Full Text
View/download PDF

20. Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – a post-hoc analysis of the PRIORITY randomized clinical trial

Author

Curovic, Viktor, primary, Tofte, Nete, additional, Lindhardt, Morten, additional, Adamova, Katarina, additional, Bakker, Stephan J.L., additional, Beige, Joachim, additional, Beulens, Joline W.J., additional, Birkenfeld, Andreas L., additional, Currie, Gemma, additional, Delles, Christian, additional, Dimos, Ingo, additional, Francová, Lidmila, additional, Frimodt-Møller, Marie, additional, Girman, Peter, additional, Göke, Rüdiger, additional, Hansen, Tine W., additional, Havrdova, Tereza, additional, Kooy, Adriaan, additional, Laverman, Gozewijnw D., additional, Mischak, Harald, additional, Navis, Gerjan, additional, Nijpels, Giel, additional, Noutsou, Marina, additional, Ortiz, Alberto, additional, Parvanova, Aneliya, additional, Persson, Frederik, additional, Petrie, John R., additional, Ruggenenti, Piero L., additional, Rutters, Femke, additional, Rychlík, Ivan, additional, Siwy, Justyna, additional, Spasovski, Goce, additional, Speeckaert, Marijn, additional, Trillini, Matias, additional, Zürbig, Petra, additional, Leyen, Heiko von der, additional, and Rossing, Peter, additional

Published
2022
Full Text
View/download PDF

21. 2022-RA-205-ESGO Circulating HPV DNA in cervical cancer: a marker for early detection of relapse

Author

Jeannot, Emmanuelle, primary, Latouche, Aurélien, additional, Bonneau, Claire, additional, Bataillon, Guillaume, additional, Chérif, Linda Larbi, additional, Popovic, Marina, additional, Rochefordière, Anne de la, additional, Lecuru, Fabrice, additional, Fourchotte, Virginie, additional, Jordanova, Ekaterina, additional, Leyen, Heiko von der, additional, Tran-Perennou, Carine, additional, Marie-Emmanuelle, Legrier, additional, Tourneau, Christophe Le, additional, Bièche, Ivan, additional, Rouzier, Roman, additional, Berns, Els, additional, Kamal, Maud, additional, and Scholl, Suzy, additional

Published
2022
Full Text
View/download PDF

22. Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection : a prospective multicentre cohort study

Author

Staessen, Jan A., Wendt, Ralph, Yu, Yu-Ling, Kalbitz, Sven, Thijs, Lutgarde, Siwy, Justyna, Raad, Julia, Metzger, Jochen, Neuhaus, Barbara, Papkalla, Armin, von der Leyen, Heiko, Mebazaa, Alexandre, Dudoignon, Emmanuel, Spasovski, Goce, Milenkova, Mimoza, Canevska-Taneska, Aleksandra, Salgueira Lazo, Mercedes, Psichogiou, Mina, Rajzer, Marek W., Fuławka, Łukasz, Dzitkowska-Zabielska, Magdalena, Weiss, Guenter, Feldt, Torsten, Stegemann, Miriam, Normark, Johan, Zoufaly, Alexander, Schmiedel, Stefan, Seilmaier, Michael, Rumpf, Benedikt, Banasik, Mirosław, Krajewska, Magdalena, Catanese, Lorenzo, Rupprecht, Harald D., Czerwieńska, Beata, Peters, Björn, Nilsson, Åsa, Rothfuss, Katja, Lübbert, Christoph, Mischak, Harald, Beige, Joachim, Staessen, Jan A., Wendt, Ralph, Yu, Yu-Ling, Kalbitz, Sven, Thijs, Lutgarde, Siwy, Justyna, Raad, Julia, Metzger, Jochen, Neuhaus, Barbara, Papkalla, Armin, von der Leyen, Heiko, Mebazaa, Alexandre, Dudoignon, Emmanuel, Spasovski, Goce, Milenkova, Mimoza, Canevska-Taneska, Aleksandra, Salgueira Lazo, Mercedes, Psichogiou, Mina, Rajzer, Marek W., Fuławka, Łukasz, Dzitkowska-Zabielska, Magdalena, Weiss, Guenter, Feldt, Torsten, Stegemann, Miriam, Normark, Johan, Zoufaly, Alexander, Schmiedel, Stefan, Seilmaier, Michael, Rumpf, Benedikt, Banasik, Mirosław, Krajewska, Magdalena, Catanese, Lorenzo, Rupprecht, Harald D., Czerwieńska, Beata, Peters, Björn, Nilsson, Åsa, Rothfuss, Katja, Lübbert, Christoph, Mischak, Harald, and Beige, Joachim

Abstract

Background: The SARS-CoV-2 pandemic is a worldwide challenge. The CRIT-CoV-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression from SARS-CoV-2. After the interim analysis presented for the German Government, here, we aimed to analyse the full dataset to consolidate the findings and propose potential clinical applications of this biomarker. Methods: CRIT-CoV-U was a prospective multicentre cohort study. In eight European countries (Austria, France, Germany, Greece, North Macedonia, Poland, Spain, and Sweden), 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression and receiver operating characteristic curve analysis with a comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalisation costs adjusted for the gross per capita domestic product of each country. Findings: From June 30 to Nov 19, 2020, 228 participants were recruited, and from April 30, 2020, to April 14, 2021, 784 participants were recruited, resulting in a total of 1012 participants. The entry WHO scores were 1–3 in 445 (44%) participants, 4–5 in 529 (52%) participants, and 6 in 38 (4%) participants; and of all participants, 119 died and 271 had disease progression. The odds ratio (OR) associated with COV50 in all 1012 participants for death was 2·44 (95% CI 2·05–2·92) unadjusted and 1·67 (1·34–2·07) when adjusted for sex, age, BMI, comorbidities, and baseline WHO score; and for disease progression, the OR was 1·79 (1·60–2·01) when unadjusted and 1·63 (1·41–1·91) when adjusted (p<0·0001 for all). The predictive accuracy of the optimised COV50

Published
2022
Full Text
View/download PDF

25. Predictive Performance and Clinical Application of COV50, A Urinary Proteomic Biomarker in Early COVID-19 Infection: A Cohort Study

Author

Staessen, Jan, primary, Wendt, Ralph, additional, Yu, Yu-Ling, additional, Kalbitz, Sven, additional, Thijs, Lutgarde, additional, Siwy, Justyna, additional, Raad, Julia, additional, Metzger, Jochen, additional, Neuhaus, Barbara, additional, Papkalla, Armin, additional, von der Leyen, Heiko, additional, Mebazaa, Alexandre, additional, Dudoignon, Emmanuel, additional, Spasovski, Goce, additional, Milenkova, Mimoza, additional, Canevska-Tanevska, Aleksandra, additional, Psichogiou, Mina, additional, Rajzer, Marek W., additional, Fulawka, Lukasz, additional, Dzitkowska-Zabielska, Magdalena, additional, Weiss, Günter, additional, Feldt, Torsten, additional, Stegemann, Miriam Songa, additional, Normark, Johan, additional, Zoufaly, Alexander, additional, Schmiedel, Stefan, additional, Seilmaier, Michael, additional, Rumpf, Benedikt, additional, Banasik, Miroslaw, additional, Krajewska, Magdalena, additional, Catanese, Lorenzo, additional, Rupprecht, Harald, additional, Czerwienska, Beata, additional, Peters, Björn, additional, Nilsson, Asa, additional, Rothfuss, Katja, additional, Lübbert, Christoph, additional, Mischak, Harald, additional, Beige, Joachim, additional, and Investigators, CRIT-Cov-U, additional

Published
2022
Full Text
View/download PDF

26. European survey on national harmonization in clinical research

Author

Magnin, Annette, Iversen, Valentina Cabral, Calvo, Gonzalo, Čečetková, Beata, Dale, Ola, Demlová, Regina, Blaskó, György, Keane, Fionnuala, Kovacs, Gabor L., Levy‐Marchal, Claire, Monteiro, Emilia C., Palmisano, Lucia, Pella, Daniel, Portolés, Antonio, Rascol, Olivier, Schmid, Caecilia, Tay, Fabian, von der Leyen, Heiko, Ohmann, Christian, and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Subjects
Research Report, Medicine (General), R5-920, clinical research, EU 536/2014, harmonization of processes, Research Reports, survey, clinical trial, ECRIN, clinical study, Public aspects of medicine, RA1-1270
Abstract

Background Clinical trials remain key to the development of evidence‐based medical practice. However, they are becoming increasingly complex, mainly in a multinational setting. To address these challenges, the European Union (EU) adopted the Clinical Trial Regulation EU No. 536/2014 (CTR). Once in force, the CTR will lead to more consistent rules and simplification of procedures for conducting clinical trials throughout the EU. Existing harmonization initiatives and “research infrastructures” for clinical trials may facilitate this process. This publication offers a snapshot of the current level of harmonization activities in academic clinical research in Europe. Methods A survey was performed among the member and observer countries of the European Clinical Research Infrastructure Network (ECRIN), using a standardized questionnaire. Three rounds of data collection were performed to maximize completeness and comparability of the received answers. The survey aimed to describe the harmonization of academic clinical research processes at national level, to facilitate the exchange of expertise and experience among countries, and to identify new fields of action. Results Most scientific partners already have in place various working groups and harmonization activities at national level. Furthermore, they are involved in and open to sharing their know‐how and documents. Since harmonization was mainly a bottom‐up approach up until now, the extent and topics dealt with are diverse and there is only little cross‐networking and cross‐country exchange so far. Conclusions Currently, the ECRIN member countries offer a very solid base and collaborative spirit for further aligning processes and exchanging best practices for clinical research in Europe. They can support a smooth implementation of the EU CTR and may act as single contact with consolidated expertise in a country.

Published
2021

28. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

Author

Jeannot, Emmanuelle, primary, Latouche, Aurélien, additional, Bonneau, Claire, additional, Calméjane, Marie-Ange, additional, Beaufort, Corine, additional, Ruigrok-Ritstier, Kirsten, additional, Bataillon, Guillaume, additional, Larbi Chérif, Linda, additional, Dupain, Célia, additional, Lecerf, Charlotte, additional, Popovic, Marina, additional, de la Rochefordière, Anne, additional, Lecuru, Fabrice, additional, Fourchotte, Virginie, additional, Jordanova, Ekaterina S., additional, von der Leyen, Heiko, additional, Tran-Perennou, Carine, additional, Legrier, Marie-Emmanuelle, additional, Dureau, Sylvain, additional, Raizonville, Laurence, additional, Bello Roufai, Diana, additional, Le Tourneau, Christophe, additional, Bièche, Ivan, additional, Rouzier, Roman, additional, Berns, Els M.J.J., additional, Kamal, Maud, additional, and Scholl, Suzy, additional

Published
2021
Full Text
View/download PDF

29. A specific urinary peptidomic profile predicts outcome in SARS-CoV-2 -infected patients

Author

Wendt, Ralph, Lutgarde Thijs, Neuhaus, Barbara, Dudoignon, Emmanuel, Mebazaa, Alexandre, Milenkova, Mimoza, Canevska-Tanevska, Aleksandra, Czerwieńska, Beata, Nilsson, Åsa, Schwab, Matthias, Rothfuss, Katja, Metzger, Jochen, Beige, Joachim Hartmut, Siwy, Justyna Jantos, Kalbitz, Sven, Von Der Leyen, Heiko E., Spasovski, Goce, Wiecek, Andrzej, Peters, Björn, Lübbert, Christoph, and Staessen, Jan A

Published
2021
Full Text
View/download PDF

30. Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer

Author

Jeannot, Emmanuelle, Latouche, Aurelien, Bonneau, Claire, Calmejane, Marie Ange, Beaufort, Corine, Ruigrok-Ritstier, Kirsten, Bataillon, Guillaume, Cherif, Linda Larbi, Dupain, Celia, Lecerf, Charlotte, Popovic, Marina, de la Rochefordiere, Anne, Lecuru, Fabrice, Fourchotte, Virginie, Jordanova, Ekaterina S., von der Leyen, Heiko, Tran-Perennou, Carine, Legrier, Marie Emmanuelle, Dureau, Sylvain, Raizonville, Laurence, Roufai, Diana Bello, Le Tourneau, Christophe, Bieche, Ivan, Rouzier, Roman, Berns, Els M.J.J., Kamal, Maud, Scholl, Suzy, Jeannot, Emmanuelle, Latouche, Aurelien, Bonneau, Claire, Calmejane, Marie Ange, Beaufort, Corine, Ruigrok-Ritstier, Kirsten, Bataillon, Guillaume, Cherif, Linda Larbi, Dupain, Celia, Lecerf, Charlotte, Popovic, Marina, de la Rochefordiere, Anne, Lecuru, Fabrice, Fourchotte, Virginie, Jordanova, Ekaterina S., von der Leyen, Heiko, Tran-Perennou, Carine, Legrier, Marie Emmanuelle, Dureau, Sylvain, Raizonville, Laurence, Roufai, Diana Bello, Le Tourneau, Christophe, Bieche, Ivan, Rouzier, Roman, Berns, Els M.J.J., Kamal, Maud, and Scholl, Suzy

Abstract

Purpose: Almost all cervical cancers are caused by human papillomavirus (HPV) and patients with advanced stage are at high risk for relapse. Circulating HPV DNA (HPV ctDNA) may serve as a residual tumor marker at the end of chemoradiation or to predict relapse during the follow-up period. Experimental Design: We analyzed serum samples from 94 HPV16- or HPV18-related CCs from the BioRAIDs prospective cohort. Samples were collected before and after treatment and during an 18-month follow-up period. Using digital droplet PCR (ddPCR), we assessed the relevance of circulating HPV E7 gene as a marker for residual disease compared to HPV integration site and PIK3CA mutations. Finally, the prognostic impact of circulating HPV E7 gene was assessed with its prediction value of relapse. Results: HPV E7 gene was the most sensitive tumor marker, superior to both HPV integration sites and PIK3CA mutations in serum. Circulating HPV DNA (HPV ctDNA) was detected in 63% (59/94) of patients, before treatment. HPV ctDNA detection in serum sample was associated with high FIGO stage (P ¼ 0.02) and para-aortic lymph node involvement (P ¼ 0.01). The level of HPV ctDNA was positively correlated with HPV copy number in the tumor (R ¼ 0.39, P < 0.001). Complete clearance of HPV ctDNA by the end of treatment was significantly associated with a longer PFS (P < 0.0001). Patients with persistent HPV ctDNA in serum relapsed with a median time of 10 months (range, 2-15) from HPV ctDNA detection. Conclusions: HPV ctDNA detection is a useful marker to predict relapse in cervical cancer.

Published
2021

31. Corrigendum to ‘clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome’

Author

Scholl, Suzy, Popovic, Marina, Rochefordiere, Anne de la, Girard, Elodie, Dureau, Sylvain, Mandic, Aljosa, Koprivsek, Katarina, Samet, Nina, Craina, Marius, Margan, Madalin, Samuels, Sanne, Zijlmans, Henry, Kenter, Gemma, Hillemanns, Peter, Dema, Sorin, Dema, Alis, Malenkovic, Goran, Djuran, Branislav, Floquet, Anne, Garbay, Delphine, Guyon, Frédéric, Colombo, Pierre Emmanuel, Fabbro, Michel, Kerr, Christine, Ngo, Charlotte, Lecuru, Fabrice, del Campo, Eleonor Rivin, Coutant, Charles, Marchal, Frédéric, Mesgouez-Nebout, Nathalie, Fourchotte, Virginie, Feron, Jean Guillaume, Morice, Philippe, Deutsch, Eric, Wimberger, Pauline, Classe, Jean-Marc, Gleeson, Noreen, Leyen, Heiko von der, Minsat, Mathieu, Dubot, Coraline, Gestraud, Pierre, Kereszt, Attila, Nagy, Istvan, Balint, Balazs, Berns, Els, Jordanova, Ekaterina, de Saint-Jorre, Nicolas, Savignoni, Alexia, Servant, Nicolas, Hupe, Philippe, de Koning, Leanne, Fumoleau, Pierre, Rouzier, Roman, and Kamal, Maud

Published
2020
Full Text
View/download PDF

32. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy

Author

Siwy, Justyna, Schanstra, Joost P., Argiles, Angel, Bakker, Stephan J.L., Beige, Joachim, Boucek, Petr, Brand, Korbinian, Delles, Christian, Duranton, Flore, Fernandez-Fernandez, Beatriz, Jankowski, Marie-Luise, Al Khatib, Mohammad, Kunt, Thomas, Lajer, Maria, Lichtinghagen, Ralf, Lindhardt, Morten, Maahs, David M, Mischak, Harald, Mullen, William, Navis, Gerjan, Noutsou, Marina, Ortiz, Alberto, Persson, Frederik, Petrie, John R., Roob, Johannes M., Rossing, Peter, Ruggenenti, Piero, Rychlik, Ivan, Serra, Andreas L., Snell-Bergeon, Janet, Spasovski, Goce, Stojceva-Taneva, Olivera, Trillini, Matias, von der Leyen, Heiko, Winklhofer-Roob, Brigitte M., Zürbig, Petra, and Jankowski, Joachim

Published
2014
Full Text
View/download PDF

33. Corrigendum to ‘clinical and genetic landscape of treatment naive cervical cancer:Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome’ (EBioMedicine (2019) 43 (253–260), (S2352396419302142), (10.1016/j.ebiom.2019.03.069))

Author

Scholl, Suzy, Popovic, Marina, de la Rochefordiere, Anne, Girard, Elodie, Dureau, Sylvain, Mandic, Aljosa, Koprivsek, Katarina, Samet, Nina, Craina, Marius, Margan, Madalin, Samuels, Sanne, Zijlmans, Henry, Kenter, Gemma, Hillemanns, Peter, Dema, Sorin, Dema, Alis, Malenkovic, Goran, Djuran, Branislav, Floquet, Anne, Garbay, Delphine, Guyon, Federic, Colombo, Pierre Emmanuel, Fabbro, Michel, Kerr, Christine, Ngo, Charlotte, Lecuru, Fabrice, del Campo, Eleonor Rivin, Coutant, Charles, Marchal, Frederic, Mesgouez-Nebout, Nathalie, Fourchotte, Virginie, Feron, Jean Guillaume, Morice, Philippe, Deutsch, Eric, Wimberger, Pauline, Classe, Jean-Marc, Gleeson, Noreen, von der Leyen, Heiko, Minsat, Mathieu, Dubot, Coraline, Gestraud, Pierre, Kereszt, Attila, Nagy, Istvan, Balint, Balazs, Berns, Els, Jordanova, Ekaterina, de Saint-Jorre, Nicolas, Savignoni, Alexia, Servant, Nicolas, Hupe, Philippe, de Koning, Leanne, Fumoleau, Pierre, Rouzier, Roman, and Kamal, Maud

Abstract

The authors wish to clarify that the authors Aljosa Mandic, Katarina Koprivsek, and Goran Malenkovic are also affiliated with Faculty of Medicine Novi Sad, University of Novi Sad, Serbia, as well as Gynecologic Oncology Department Clinic for Operative Oncology, Institute of Oncology of Vojvodina, Serbia.

Published
2020
Full Text
View/download PDF

34. Additional file 1 of Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients

Author

Scheper, Verena, Schmidtheisler, Melanie, Lasch, Florian, Leyen, Heiko Von Der, Koch, Armin, Schwieger, Jana, Büchner, Andreas, Lesinski-Schiedat, Anke, and Lenarz, Thomas

Abstract

Additional file 1. Includes the general medical history for all patients in the ITT-set as Supplement 1. Ear specific medical history for the implanted ear is stated in Supplement 2 of the additional file 1. Supplement 3 shows the aetiology of the implanted ear. Concomitant medication for the ITT-set summarized by events is stated in Supplement 4. Supplement 5 gives the hearing loss over time at 500 Hz with imputation of 110 dB if the upper detection limit is reached or 120 dB if the measurement is missing. Supplement 6 reports the hearing preservation measured by air conducted audiometry at 500 Hz including all timepoints analyzed in the modified ITT population using a mixed model with change from baseline as dependent variable and treatment, baseline hearing threshold, surgeon, electrode length, electrode length - visit interaction and visit-treatment interaction as fixed effects. The mixed model for repeated measures was conducted adjusting for either the planned electrode length (Supplement Table 6.1) as was done in the primary analysis model, or by adjusting for the used electrode length (Supplement Table 6.2). The estimated mean hearing loss at all time points with 95%-confidence intervals based on the mixed model for repeated measures adjusted for the planned electrode length is illustrated in supplementary figure 6. AEs are listed in supplement 7.

Published
2020
Full Text
View/download PDF

36. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY):a prospective observational study and embedded randomised placebo-controlled trial

Author

Tofte, Nete, Lindhardt, Morten, Adamova, Katarina, Bakker, Stephan J.L., Beige, Joachim, Beulens, Joline W.J., Birkenfeld, Andreas L., Currie, Gemma, Delles, Christian, Dimos, Ingo, Francová, Lidmila, Frimodt-Møller, Marie, Girman, Peter, Göke, Rüdiger, Havrdova, Tereza, Heerspink, Hiddo J.L., Kooy, Adriaan, Laverman, Gozewijn D., Mischak, Harald, Navis, Gerjan, Nijpels, Giel, Noutsou, Marina, Ortiz, Alberto, Parvanova, Aneliya, Persson, Frederik, Petrie, John R., Ruggenenti, Piero L., Rutters, Femke, Rychlík, Ivan, Siwy, Justyna, Spasovski, Goce, Speeckaert, Marijn, Trillini, Matias, Zürbig, Petra, von der Leyen, Heiko, Rossing, Peter, Zimmermann, Silke, Rädisch, Brit, Hävemeier, Anika, Busmann, Annette, Wittkop, Ulrike, Curovic, Viktor R., Tougaard, Ninna H., Hansen, Tine W., Hansen, Christian S., Zobel, Emilie H., Laursen, Jens C., Juhl, Tina R., Lundgaard, Anne G., Lajer, Maria, Tofte, Nete, Lindhardt, Morten, Adamova, Katarina, Bakker, Stephan J.L., Beige, Joachim, Beulens, Joline W.J., Birkenfeld, Andreas L., Currie, Gemma, Delles, Christian, Dimos, Ingo, Francová, Lidmila, Frimodt-Møller, Marie, Girman, Peter, Göke, Rüdiger, Havrdova, Tereza, Heerspink, Hiddo J.L., Kooy, Adriaan, Laverman, Gozewijn D., Mischak, Harald, Navis, Gerjan, Nijpels, Giel, Noutsou, Marina, Ortiz, Alberto, Parvanova, Aneliya, Persson, Frederik, Petrie, John R., Ruggenenti, Piero L., Rutters, Femke, Rychlík, Ivan, Siwy, Justyna, Spasovski, Goce, Speeckaert, Marijn, Trillini, Matias, Zürbig, Petra, von der Leyen, Heiko, Rossing, Peter, Zimmermann, Silke, Rädisch, Brit, Hävemeier, Anika, Busmann, Annette, Wittkop, Ulrike, Curovic, Viktor R., Tougaard, Ninna H., Hansen, Tine W., Hansen, Christian S., Zobel, Emilie H., Laursen, Jens C., Juhl, Tina R., Lundgaard, Anne G., and Lajer, Maria

Abstract

Background: Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone. Methods: In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function based on estimated glomerular filtration rate (eGFR; observational cohort). Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events were recorded for the intention-to-treat population (trial cohort). This study is registered with the EU Clinical Trials Register (EudraCT 20120-004523-4) and ClinicalTrials.gov (NCT02040441) and is completed. Findings: Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic patte

Published
2020

37. SAT-152 - Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Author

Anastasiou, Olympia Aevdoxia, Caruntu, Florin Alexandru, Curescu, Manuela Gabriela, Yalcin, Kendal, Akarca, Ulus S, Gurel, Selim, Zeuzem, Stefan, Erhardt, Andreas, Lüth, Stefan, Papatheodoridis, George, Keskin, Onur, Port, Kerstin, Radu, Monica, Celen, Mustafa, Idilman, Ramazan, Heidrich, Benjamin, Mederacke, Ingmar, von der Leyen, Heiko, Kahlhöfer, Julia, von Karpowitz, Maria, Hardtke, Svenja, Cornberg, Markus, Yurdaydin, Cihan, and Wedemeyer, Heiner

Published
2023
Full Text
View/download PDF

39. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Author

Weissinger, Eva M., primary, Metzger, Jochen, additional, Schleuning, Michael, additional, Schmid, Christoph, additional, Messinger, Diethelm, additional, Beutel, Gernot, additional, Wagner-Drouet, Eva-Maria, additional, Schetelig, Johannes, additional, Baurmann, Herrad, additional, Rank, Andreas, additional, Stolzl, Friedrich, additional, Schäfer-Eckart, Kerstin, additional, Westphal, Karin, additional, Bethge, Wolfgang, additional, von Harsdorf, S., additional, Bunjes, Donald W., additional, Heidenreich, Daniela, additional, Klein, Stefan, additional, Holler, Ernst, additional, Kreipe, Hans H., additional, Jonigk, Danny, additional, Türüchanow, Irina, additional, Raad, Julia, additional, Papkalla, Armin, additional, von der Leyen, Heiko, additional, Hambach, Lothar, additional, Hamwi, Iyas, additional, Ehrlich, Steve, additional, Krauter, Jurgen, additional, Stadler, Michael, additional, and Ganser, Arnold, additional

Published
2020
Full Text
View/download PDF

40. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Author

Tofte, Nete, primary, Lindhardt, Morten, additional, Adamova, Katarina, additional, Bakker, Stephan J L, additional, Beige, Joachim, additional, Beulens, Joline W J, additional, Birkenfeld, Andreas L, additional, Currie, Gemma, additional, Delles, Christian, additional, Dimos, Ingo, additional, Francová, Lidmila, additional, Frimodt-Møller, Marie, additional, Girman, Peter, additional, Göke, Rüdiger, additional, Havrdova, Tereza, additional, Heerspink, Hiddo J L, additional, Kooy, Adriaan, additional, Laverman, Gozewijn D, additional, Mischak, Harald, additional, Navis, Gerjan, additional, Nijpels, Giel, additional, Noutsou, Marina, additional, Ortiz, Alberto, additional, Parvanova, Aneliya, additional, Persson, Frederik, additional, Petrie, John R, additional, Ruggenenti, Piero L, additional, Rutters, Femke, additional, Rychlík, Ivan, additional, Siwy, Justyna, additional, Spasovski, Goce, additional, Speeckaert, Marijn, additional, Trillini, Matias, additional, Zürbig, Petra, additional, von der Leyen, Heiko, additional, Rossing, Peter, additional, Zimmermann, Silke, additional, Rädisch, Brit, additional, Hävemeier, Anika, additional, Busmann, Annette, additional, Wittkop, Ulrike, additional, Neuhaus, Barbara, additional, Ax-Smolarski, Regina, additional, Zieglschmid, Veit, additional, Bollweber, Eva, additional, Wölk, Heidrun, additional, Curovic, Viktor R., additional, Tougaard, Ninna H., additional, Eickhoff, Mie K., additional, Pilemann-Lyberg, Sascha, additional, Winther, Signe A., additional, Rosenlund, Signe V., additional, Hansen, Tine W., additional, von Scholten, Bernt J., additional, Hansen, Christian S., additional, Zobel, Emilie H., additional, Laursen, Jens C., additional, Theilade, Simone, additional, Jelstrup, Lone, additional, Juhl, Tina R., additional, Riis, Dorthe, additional, Hermann, Jessie A., additional, Lundgaard, Anne G., additional, Halkjær, Maja L.D., additional, Aabo, Lene, additional, Frost Lerche, Therese, additional, Lajer, Maria, additional, Stefansen, Rikke J., additional, Campbell, Maria A., additional, Durban, Annika, additional, Raad, Julia, additional, Prigge, Michael, additional, Schiemann, Marco, additional, Wilson, Robbie, additional, Kean, Sharon, additional, Douglas, Elizabeth, additional, Surtees, Pamela, additional, Gant, Christina, additional, Yeung, Stanley M.H., additional, Hagedoorn, Ilse, additional, Flynn, Joanne, additional, Galloway, Joe, additional, Brooksbank, Katriona, additional, Aparicio, Carolina, additional, Iliev, Ilian P., additional, Nones, Francesco, additional, Lo Bue, Francesca, additional, Melacini, Daniela, additional, Cugini, Daniela, additional, Prandini, Silvia, additional, Lecchi, Verusca, additional, Yakymchuk, Svitlana, additional, Gherardi, Giulia, additional, Villa, Alessandro, additional, Villa, Davide, additional, Gaspari, Flavio, additional, Cannata, Antonio N., additional, Ferrari, Silvia, additional, Stucchi, Nadia, additional, Albrechtová, Šárka, additional, Eldeik, Elina, additional, Amanaki, Renata, additional, Fernandez-Fernandez, Beatriz, additional, Sanchez-Rodriguez, Jinny, additional, Vázquez, Clotilde, additional, Sanz, Ana B., additional, Sanchez-Niño, Maria D., additional, Ramos, Adrian M., additional, Gonzalo, Maria Á., additional, Schmidt, Ulrike, additional, Selim, Gjulsen, additional, Gjorgovski, Tatjana, additional, Stratrova, Slavica S., additional, Stojceva-Taneva, Olivera, additional, Schutten-Westerneng, Petra, additional, Wierbos, Brenda, additional, Huvers, Frank, additional, De Bruin, Anneke K., additional, Lapauw, Bruno, additional, de Man, Elsie, additional, Rokegem, Kelly, additional, Inion, Sabien, additional, Kreutzmann, Kristin, additional, Dewettinck, Isabelle, additional, Boukens-de Graaf, Caroline, additional, Clerc-de Jong, Ferrina, additional, Entius, Jannet, additional, Nannings, Marian, additional, van Steenderen, Suzy, additional, Petry, Friedrich W., additional, and Kilic, Ceyda, additional

Published
2020
Full Text
View/download PDF

41. European survey on national harmonization in clinical research

Author

Magnin, Annette, primary, Iversen, Valentina Cabral, additional, Calvo, Gonzalo, additional, Čečetková, Beata, additional, Dale, Ola, additional, Demlová, Regina, additional, Blaskó, György, additional, Keane, Fionnuala, additional, Kovacs, Gabor L., additional, Levy‐Marchal, Claire, additional, Monteiro, Emilia C., additional, Palmisano, Lucia, additional, Pella, Daniel, additional, Portolés, Antonio, additional, Rascol, Olivier, additional, Schmid, Caecilia, additional, Tay, Fabian, additional, Leyen, Heiko, additional, and Ohmann, Christian, additional

Published
2020
Full Text
View/download PDF

44. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene

Author

Leyen, Heiko E. von der, Gibbons, Gary H., Morishita, Ryuichi, Lewis, Neil P., Zhang, Lunan, Nakajima, Masatoshi, Kaneda, Yasufumi, Cooke, John P., and Dzau, Victor J.

Subjects
Vascular smooth muscle -- Research, Genetic transformation -- Observations, Enzymes -- Research, Science and technology
Abstract

A study of the factors influencing vascular smooth muscle cell accumulation indicate that endothelial cell nitric oxide synthase (ec-NOS) is an endogenous inhibitor of in vivo formation of vascular lesions. A Sendai virus/liposome in vivo gene transfer technique enables total expression of ec-NOS in vessel walls. The vascular reactivity of the damaged vessel and NO synthesis increases with ec-NOS gene transfection.

Published
1995

47. Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial

Author

Sauer, Martin G., primary, Lang, Peter J., additional, Albert, Michael H., additional, Bader, Peter, additional, Creutzig, Ursula, additional, Eyrich, Matthias, additional, Greil, Johann, additional, Gruhn, Bernd, additional, Holter, Wolfgang, additional, Klingebiel, Thomas, additional, Kremens, Bernhard, additional, von der Leyen, Heiko, additional, Mauz-Körholz, Christine, additional, Meisel, Roland, additional, Mischke, Kirsten, additional, Müller, Ingo, additional, Niemeyer, Charlotte M., additional, Peters, Christina, additional, Pohler, Christine, additional, Reinhardt, Dirk, additional, Burkhardt, Birgit, additional, Schlegel, Paul G., additional, Schulz, Ansgar S., additional, Schrum, Johanna, additional, Sedlacek, Petr, additional, Strahm, Brigitte, additional, Woessmann, Wilhelm, additional, Handgretinger, Rupert, additional, Zimmermann, Martin, additional, and Borkhardt, Arndt, additional

Published
2019
Full Text
View/download PDF

48. Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial

Author

Sauer, Martin G., primary, Lang, Peter J., additional, Albert, Michael H., additional, Bader, Peter, additional, Creutzig, Ursula, additional, Eyrich, Matthias, additional, Greil, Johann, additional, Gruhn, Bernd, additional, Holter, Wolfgang, additional, Klingebiel, Thomas, additional, Kremens, Bernhard, additional, von der Leyen, Heiko, additional, Mauz-Körholz, Christine, additional, Meisel, Roland, additional, Mischke, Kirsten, additional, Müller, Ingo, additional, Niemeyer, Charlotte M., additional, Peters, Christina, additional, Pohler, Christine, additional, Reinhardt, Dirk, additional, Burkhardt, Birgit, additional, Schlegel, Paul G., additional, Schulz, Ansgar S., additional, Schrum, Johanna, additional, Sedlacek, Petr, additional, Strahm, Brigitte, additional, Woessmann, Wilhelm, additional, Handgretinger, Rupert, additional, Zimmermann, Martin, additional, and Borkhardt, Arndt, additional

Published
2019
Full Text
View/download PDF

49. Clinical and Genetic Landscape of Treatment Naive Cervical Cancer: Alterations in PIK3CA and in Epigenetic Modulators Associated with Sub-Optimal Outcome

Author

Scholl, Suzy, primary, Popovic, Marina, additional, de la Rochefordiere, Anne, additional, Girard, Elodie, additional, Dureau, Sylvain, additional, Mandic, Aliosa, additional, Koprivsek, Katarina, additional, Samet, Nina, additional, Craina, Marius, additional, Margan, Madalin, additional, Samuels, Sanne, additional, Zijlmans, Henry, additional, Kenter, Gemma, additional, Hillemanns, Peter, additional, Dema, Sorin, additional, Dema, Akis, additional, Malenkovic, Goran, additional, Djuran, Branislav, additional, Floquet, Anne, additional, Garbay, Delphine, additional, Guyon, Frédéric, additional, Colombo, Pierre Emmanuel, additional, Fabbro, Michel, additional, Kerr, Christine, additional, Ngo, Charlotte, additional, Lecuru, Fabrice, additional, Rivin del Campo, Eleonor, additional, Coutant, Charles, additional, Marchal, Frédéric, additional, Mesgouez-Nebout, Nathalie, additional, Fourchotte, Virginie, additional, Feron, Jean Guillaume, additional, Morice, Philippe, additional, Deutsch, Eric, additional, Wimberger, Pauline, additional, Classe, Jean-Marc, additional, Gleeson, Noreen, additional, von der Leyen, Heiko, additional, Minsat, Mathieu, additional, Dubot, Coraline, additional, Kereszt, Attila, additional, Nagy, Istvan, additional, Balint, Balazs, additional, Berns, Els Petronella, additional, Jordanova, Ekaterina, additional, de Saint-Jorre, Nicolas, additional, Savignoni, Alexia, additional, Servant, Nicolas, additional, Hupe, Philippe, additional, de Koning, Leanne, additional, Fumoleau, Pierre, additional, Rouzier, Roman, additional, and Kamal, Maud, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results